DDInter672 DDInter1676
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Escitalopram {u} (Compound) resembles {v} (Compound) Citalopram
Escitalopram {u} (Compound) binds {v} (Gene) CYP3A4
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
Escitalopram {u} (Compound) palliates {v} (Disease) bipolar disorder
Escitalopram {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin Uptake Inhibitors
Escitalopram {u} (Compound) downregulates {v} (Gene) VAT1
Escitalopram {u} (Compound) causes {v} (Side Effect) Dysmenorrhoea
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Miconazole
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Escitalopram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thiethylperazine
Escitalopram (Compound) resembles Citalopram (Compound)
Escitalopram (Compound) binds CYP3A4 (Gene)
Escitalopram (Compound) upregulates RRS1 (Gene)
Escitalopram (Compound) palliates bipolar disorder (Disease)
Escitalopram (Compound) is included by Serotonin Uptake Inhibitors (Pharmacologic Class)
Escitalopram (Compound) downregulates VAT1 (Gene)
Escitalopram (Compound) causes Dysmenorrhoea (Side Effect)
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Miconazole
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine